Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Brian, If you are reading this board
It is no mystery. in the space of a little more than a year S & L diluted the OS by about 100 million shares. As I've said before, I believe that the warrant issue is nearing an end and that S & L will soon become just a large shareholder. Then hopefully the BOD will revisit the dividend, which had a dilutive effect on the stock especially when it was also given to warrant holders, and concentrate on a more agressive share repurchase program.
Share
New Message
Please login to post a reply